San Francisco Bay Area biotech stories.
Tuesday, August 21, 2012
Gilead drops artery disease drug cicletanine after trial failure
Gilead Sciences Inc.'s
heart and lung disease drug cicletanine failed a mid-stage trial,
Dow Jones reported Tuesday
, and the company is discontinuing development of the drug.
Foster City-based Gilead (NASDAQ: GILD) picked up cicletanine, aimed at pulmonary arterial hypertension patients,
for an initial $10.9 million in May 2008
from Navitas Assets LLC.
Share to Twitter
Share to Facebook
Share to Pinterest
Post a Comment
Post Comments (Atom)